Company Overview - Paysign is a leading provider of payment solutions tailored to the life sciences industries[8] - The company has been a trusted partner for major pharmaceutical and healthcare companies for over 20 years[12] - Paysign navigates all aspects of the prepaid card lifecycle in house[13] Financial Performance - Paysign's stock price was $5.47 as of November 13, 2025, with a market cap of $337.9 million[27] - The company's TTM revenue is $74.9 million[27] - Q3 2025 Gross Profit Margin was 56.3%[27] - TTM Fully Diluted EPS is $0.13, and TTM Fully Diluted Adjusted EBITDA per Share is $0.30[27] - Cash as of September 30, 2025, was $7.5 million[27] Market and Growth - Paysign holds approximately 50% of the plasma donor compensation market as of September 30, 2025[53] - The company acquired Gamma Innovation LLC to enhance capabilities in plasma donor and pharmaceutical patient engagement technologies[62] - The 2026 U S Open-Loop Prepaid Market is estimated at $728.8 billion[73]